Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Sales | 1,608,000 | 1,511,500 | 1,582,420 | 1,500,673 | 1,470,116 |
| Cost of Goods | 91,700 | 114,900 | 105,779 | 104,232 | 102,921 |
| Gross Profit | 1,516,300 | 1,396,600 | 1,476,641 | 1,396,441 | 1,367,195 |
| Operating Expenses | 894,800 | 830,300 | 938,600 | 836,747 | 817,804 |
| Operating Income | 622,200 | 567,200 | 538,820 | 559,926 | 550,312 |
| Interest Expense | 6,900 | 6,400 | 6,016 | 6,182 | 5,401 |
| Other Income | 40,800 | 24,600 | 21,952 | 11,861 | -19,061 |
| Pre-tax Income | 656,100 | 585,400 | 554,756 | 565,605 | 525,850 |
| Income Tax | 104,700 | 107,400 | 381,248 | 177,288 | 138,106 |
| Net Income Continuous | 551,400 | 478,000 | 173,508 | 388,317 | 387,744 |
| Net Income | $551,400 | $478,000 | $173,508 | $388,317 | $387,744 |
| EPS Basic Total Ops | 5.12 | 4.44 | 1.61 | 3.64 | 3.66 |
| EPS Basic Continuous Ops | 5.12 | 4.44 | 1.62 | 3.64 | 3.66 |
| EPS Diluted Total Ops | 4.82 | 4.16 | 1.52 | 3.32 | 3.34 |
| EPS Diluted Continuous Ops | 4.82 | 4.16 | 1.52 | 3.32 | 3.34 |
| EBITDA(a) | $655,800 | $603,600 | $573,360 | $597,645 | $585,438 |